{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:45:48Z","timestamp":1774442748890,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ijantimicag.2020.106119","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T21:59:59Z","timestamp":1596059999000},"page":"106119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection"],"prefix":"10.1016","volume":"56","author":[{"given":"Helyson Lucas Bezerra","family":"Braz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Alison de Moraes","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline Diogo","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elisabete Amaral","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoel Odorico de","family":"Moraes Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Serra Azul","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-4302","authenticated-orcid":false,"given":"Roberta Jeane Bezerra","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106119_bib0001","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2014an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0002","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.abb4218","article-title":"The effect of human mobility and control measures on the COVID-19 epidemic in China","volume":"368","author":"Kraemer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus SARS-CoV-2","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0005","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0006","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0007","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0009","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"67","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0010","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202000028","article-title":"Rapid identification of potential inhibitors of SARS\u2010CoV\u20102 main protease by deep docking of 1.3 billion compounds","author":"Ton","year":"2020","journal-title":"Mol Inform"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12250-020-00204-7","article-title":"Old weapon for new enemy: drug repurposing for treatment of newly emerging viral diseases","volume":"35","author":"Guo","year":"2020","journal-title":"Virol Sin"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0015","first-page":"369:m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0016","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19","volume":"82","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0017","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0018","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19","author":"Yu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0019","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/ed100697w","article-title":"ChemSpider: an online chemical information resource","volume":"87","author":"Pence","year":"2010","journal-title":"J Chem Educ"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0020","article-title":"Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study","author":"Khaerunnisa","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0021","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0022","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0023","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.3390\/antibiotics5030029","article-title":"From erythromycin to azithromycin and new potential ribosome-binding antimicrobials","volume":"5","author":"Jeli\u0107","year":"2016","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0024","series-title":"StatPearls","article-title":"Macrolides [updated 2019 Nov 28]","author":"Patel","year":"2020"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4172\/1948-5964.1000173","article-title":"Azithromycin inhibits the replication of Zika virus","volume":"10","author":"Bosseboeuf","year":"2018","journal-title":"J Antivir Antiretrovir"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00394-19","article-title":"Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses","volume":"63","author":"Li","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0027","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","article-title":"Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process","volume":"72","author":"Tran","year":"2019","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0028","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.antiviral.2009.05.003","article-title":"Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells","volume":"83","author":"Asada","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0029","doi-asserted-by":"crossref","first-page":"e00293","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/microorganisms8010085","article-title":"The use of antimalarial drugs against viral infection","volume":"8","author":"D'Alessandro","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0031","unstructured":"ClinicalTrials.gov. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-Cov-2 virus (COVID-19) (Coalition-I). ClinicalTrials.gov ID NCT04322123. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322123[accessed 20 June 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0033","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin\u2013angiotensin system in cardiovascular disease","volume":"17","author":"Ocaranza","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0034","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: should inhibitors of the renin\u2013angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0036","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0037","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0038","article-title":"On the generation of novel ligands for SARS-CoV-2 protease and ACE2 receptor via constrained graph variational autoencoders","author":"Catapang","year":"2020","journal-title":"ChemRxiv"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0039","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.00128-13","article-title":"The spike protein of the emerging Betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies","volume":"87","author":"Gierer","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0040","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0041","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0042","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0043","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0044","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/v12020240","article-title":"Structural basis for inhibiting porcine epidemic diarrhea virus replication with the 3C-like protease inhibitor GC376","volume":"12","author":"Ye","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0046","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0047","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jconrel.2018.12.014","article-title":"Applications of \u03c0\u2013\u03c0 stacking interactions in the design of drug-delivery systems","volume":"294","author":"Zhuang","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0048","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1039\/D0CC02245D","article-title":"Regioselective synthesis and anticancer evaluation of H2O2-activatable nucleosides","volume":"56","author":"Sun","year":"2020","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0049","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41579-018-0003-6","article-title":"Autophagy during viral infection\u2014a double-edged sword","volume":"16","author":"Choi","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0050","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome\u2013lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1973","article-title":"Autophagy: the multi-purpose bridge in viral infections and host cells","volume":"28","author":"Abdoli","year":"2018","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0052","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1099\/jmm.0.000565","article-title":"A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective","volume":"66","author":"Rabaan","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0053","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0054","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0055","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0056","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0057","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0006-291X(03)01342-1","article-title":"Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS","volume":"308","author":"Chou","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0058","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0059","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0061","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J Adv Res"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0062","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0063","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/2014.12.FOCUS14748","article-title":"Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors","volume":"38","author":"Golden","year":"2015","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0064","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0066","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ijantimicag.2020.106119_bib0067","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:16Z","timestamp":1760377036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920303022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0924857920303022"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106119","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106119"}}